Denise C. Welsh1, Tyler Teceno1, Ken Ito1, Mamuro Yanagimachi1, Deirdre Scully2, Jacob Hesterman2, Yasuhiro Funahashi1, Paul J. McCracken1
1Eisai, Andover, MA, United States; 2InVicro, Boston, MA, United States
The effects of eribulin, a microtubule binding drug approved third line therapy for breast cancer, on the vasculature and tumor growth of human breast cancer mouse MX-1 tumors are compared to capecitabine, a cytotoxic. These DCE-MRI data show evidence of antivascular activity at early time points after eribulin treatment and a stabilization of tumor volume. In addition to stabilizing tumor growth over a 5 day period, we demonstrated that a single dose of 3mg/kg i.v. eribulin reduces tumor Ktrans as early as 6hrs followed by a significant increase in Ktrans by days 2 and 5.